Find Academic Supervisors

• Ophthalmology
• Cell Biology
• Diabetes
• +7 more

Przemyslaw (Mike) Sapieha is a Full Professor in the Department of Ophthalmology and holds a Canada Research Chair (Tier 1) in Retinal Cell Biology at the Université de Montréal. He also serves as an Adjunct Professor in the Department of Biochemistry and Molecular Medicine. His research focuses on understanding age-related retinal diseases, particularly the mechanisms of inflammation and metabolic influences on ocular vasculature. Sapieha leads projects on therapeutic strategies for conditions like diabetic retinopathy and age-related macular degeneration (AMD). Education: PhD from Université de Montréal (2006), followed by postdoctoral training at McGill University and Harvard Medical School. His academic roles include Director of SemaThera Inc. and Scientific Director at UNITY Biotechnology. Research Interests: Sapieha's lab explores beneficial vs. destructive inflammation in neurovascular systems, metabolic reprogramming of immunity, and therapeutic development for retinal diseases. Key areas include the role of cellular senescence, obesity, and infection history in disease progression. Grants & Projects: Leads multiple funded initiatives, including the Canada Research Chair (2022–2028), studies on obesity and AMD (BrightFocus Foundation), and immune training mechanisms in retinopathies (CIHR grants). He has secured over CAD 15 million in research funding. Awards: Honors include the 2024 Effervescence Star Award, Cogan Award (2019), and election to the Royal Society of Canada (2018). He has authored >50 peer-reviewed articles in top journals like Nature Medicine and Science . Collaborations: Directs the CRHMR research center and collaborates with institutions like Unity Biotechnology and Harvard Medical School. His lab is affiliated with the Réseau de Recherche en Santé de la Vision (RRSV).

• Computational Biology
• Systems Biology
• Genomics
• +7 more

Gary Bader is a Professor at The Donnelly Centre, University of Toronto, specializing in Computational Biology and Systems Biology. His research focuses on integrating molecular interaction networks, pathway analysis, and 'omics data to understand disease mechanisms and develop clinical models. He leads the Bader Lab, which develops computational tools like Cytoscape and Pathway Commons, and explores single-cell genomics to study tissue function, cancer, and regenerative processes. Education: BSc Biochemistry (McGill University), PhD Biochemistry (University of Toronto), Postdoc at Memorial Sloan-Kettering Cancer Center. Affiliations: Donnelly Centre, Department of Molecular Genetics, Department of Computer Science, Lunenfeld-Tanenbaum Research Institute, Princess Margaret Cancer Centre, and CIFAR MacMillan Multiscale Program. Research interests include causal mechanistic modeling of disease (e.g., pediatric ependymoma therapies), ecosystem theories of tissue function, and open-source bioinformatics tools. Recent work emphasizes single-cell and spatial transcriptomics to map cellular heterogeneity in diseases like cancer, liver pathologies, and neurological disorders. Collaborations span computational methods, stem cell biology, and clinical translation.

Jeff StuartView profile

Professor

• Mitochondrial Biology
• Cell Physiology
• Cancer Metabolism
• +7 more

Jeff Stuart is a Professor in the Department of Biological Sciences at Brock University . His research focuses on mitochondrial biology in health, aging, and disease contexts, with a particular emphasis on developing innovative tools for observing and manipulating mitochondrial networks in living cells. Key tools: MiNA (Mitochondrial Network Analysis), Hypoxio incubators, and O2/CO2 regulation systems Research platform: StuartLab GitHub for open-source scientific tools His work bridges cell physiology and applied biomedical engineering , with recent publications addressing: Cancer metabolism under physiological oxygen conditions Mitochondrial dynamics in disease states Physiological cell culture methodology Neurodegenerative disease mechanisms Thermogenic metabolism through nutritional supplements Jeff Stuart actively collaborates across disciplines, integrating bioinformatics , bioenergetics , and cellular imaging to advance experimental systems biology.

Mireille OuimetView profile

Associate Professor

• Cardiovascular Diseases
• Atherosclerosis
• Cellular Immunometabolism
• +4 more

Dr. Mireille Ouimet is an Associate Professor at the Department of Biochemistry, Microbiology and Immunology within the Faculty of Medicine at the University of Ottawa. Her research focuses on cardiovascular diseases, particularly atherosclerosis, integrating immunometabolism and autophagy pathways to develop novel therapeutic strategies. BSc Biochemistry, University of Ottawa PhD Biochemistry, University of Ottawa Postdoctoral Fellowship, New York University Dr. Ouimet's work explores autophagy-mediated lipid droplet degradation (lipophagy) as a mechanism to reverse atherosclerotic plaques, with emphasis on cholesterol homeostasis, miRNA regulation, and macrophage metabolism. Her laboratory investigates the molecular components of lipophagy for therapeutic manipulation. Recent publications highlight her contributions to understanding miRNA-controlled lipid metabolism, autophagy in atherosclerosis, and mitochondrial energy status in macrophage polarization. Collaborative studies involve nanoparticle-based imaging and immunometabolic reprogramming in cardiovascular disease.

Joe MymrykView profile

Professor

• DNA Tumor Viruses
• Human Cancers
• Virology
• +4 more

Joe Mymryk is a Professor at The University of Western Ontario, with affiliations in the Departments of Microbiology & Immunology, Otolaryngology, and Oncology. He holds the title of Distinguished Scientist at the London Regional Cancer Program and the Lawson Health Research Institute. His research focuses on mechanisms linking DNA tumor viruses (e.g., adenovirus, HPV, EBV) to human cancers, particularly viral protein interactions and their roles in cellular reprogramming. Mymryk’s work bridges virology, cancer biology, and molecular biology, with collaborations in clinical oncology and immunology. His lab investigates viral-host interactions, nuclear transport, and epigenetic regulation in cancer progression. Recent studies emphasize metabolic pathways in cancer, drug resistance mechanisms, and immune microenvironment profiling in HPV+/- tumors. He leads the Canadian Airways Research (CARE) group, advancing precision medicine approaches for head and neck cancers. His research has produced over 150 peer-reviewed articles, with active grants exploring therapeutic targets for anaplastic thyroid cancer and EBV-associated malignancies.

Wayne SneddenView profile

Professor

• Plant Molecular Biology
• Plant Biochemistry
• Calcium Signaling in Plants
• +3 more

Wayne Snedden is a Professor in the Department of Biology at Queen's University, specializing in Plant Molecular Biology and Biochemistry. His research focuses on calcium signal transduction mechanisms in plants, particularly how calmodulin and related proteins mediate responses to environmental stresses like cold, drought, and pathogen attacks. He teaches courses in introductory biology and plant physiology at both undergraduate and graduate levels. His laboratory investigates plant stress tolerance through enzymatic pathways, including the role of glutamate decarboxylase and calmodulin-like proteins in metabolic adaptation. Key findings include the discovery of CML13 and CML14 proteins' dual roles in myosin regulation and salinity response, as well as their involvement in developmental processes. His work bridges molecular mechanisms with applied goals like engineering stress-resistant crops. Teaching contributions include specialized graduate courses and lab modules in plant physiology. He maintains an active research lab with a focus on Arabidopsis thaliana and other model plants. No awards are explicitly listed in the provided materials, though his extensive publication record indicates sustained academic impact.

Philip Britz-McKibbinView profile

Professor

• Analytical biochemistry
• Analytical chemistry
• Metabolomics
• +7 more

Philip Britz-McKibbin is a Professor in the Department of Chemistry and Chemical Biology at McMaster University. He also holds associate memberships in the Department of Pathology and Molecular Medicine and the Centre for Medicinal Cannabis Research at McMaster. His laboratory is an affiliate member of The Metabolomics Innovation Centre (TMIC), Canada's national metabolomics laboratory. Dr. Britz-McKibbin is also recognized as a Cystic Fibrosis Canada Researcher. Dr. Britz-McKibbin's research focuses on bio-analytical chemistry with special emphasis on metabolomics. His laboratory develops innovative capillary electrophoresis-mass spectrometry technologies to identify and quantify clinically relevant biomarkers for early detection and diagnosis of genetic and chronic human diseases. His work spans multiple domains including children's health, nutritional sciences, metabolic diseases, and lipidomics. His recent publications demonstrate a strong trend toward clinical applications of metabolomics, particularly in pediatric health, vitamin D metabolism, inflammatory bowel diseases, and growth assessment in children. His research increasingly incorporates multi-omics approaches and population-level studies to identify biomarkers with clinical utility. Analytical biochemistry Analytical chemistry Metabolomics Clinical sciences Health sciences Human metabolism and disease Lipidomics Metabolic Diseases Dr. Britz-McKibbin has taught various courses in analytical chemistry, chemical biology, and bio-analytical chemistry at McMaster University, including Analytical Tools for Chemical Biology, Instrumental Analysis, and Introduction to Bio-Analytical Chemistry.

Paola A. MarignaniView profile

Professor

• Cancer Metabolism
• Tumor Suppressor Proteins
• Signal Transduction
• +5 more

Paola A. Marignani is a Professor in the Departments of Biochemistry and Molecular Biology and Pathology at Dalhousie University's Faculty of Medicine. She has been a department member since 2003, following postdoctoral fellowships at Harvard University and the Samuel Lunenfeld Research Institute/Ontario Cancer Institute. Her research focuses on tumor suppressors, cancer metabolism, and signal transduction, with a particular emphasis on LKB1 and Vav2 proteins. She holds a PhD in Biochemistry from McMaster University and an Executive MBA from Ivey School of Business. Education: Hon BSc, University of Windsor MSc, University of Western Ontario PhD, McMaster University Executive MBA, Ivey School of Business, Western Ontario Research Interests: The Marignani Lab investigates molecular mechanisms underlying cancer progression and neurodegenerative diseases. Key areas include: LKB1's role in tumor suppression and metabolic regulation Vav2's influence on cytoskeletal reorganization Pre-clinical drug development using animal models Single-cell genomic analysis (scRNA-seq, scATAC-seq) Funding Sources: Supported by Dalhousie Medical Research Foundation, CIHR, NSERC, and others. Current projects include biomarker identification and targeted therapeutics. Labs & Teams: The Marignani Discovery Research Laboratory employs advanced platforms such as metabolomics, epigenomics, and CRISPR-based gene editing. Lab members include postdocs, technicians, and students, with notable former trainees like Jacob Rukavina and Ramani Soundararajan.

Vilceu BordignonView profile

Associate Professor

• Sustainable crop and livestock production systems
• Human nutrition and One Health
• Animal models
• +13 more

Vilceu Bordignon serves as an Associate Professor in the Department of Animal Science at McGill University's Macdonald Campus, focusing on sustainable agricultural systems and interdisciplinary connections between animal production, human health, and environmental sustainability. His research spans critical domains in modern agricultural science: Sustainable crop and livestock production systems addressing food security challenges Human nutrition and One Health frameworks integrating animal, human, and ecosystem health Advanced biotechnological applications including reproductive biology, genome editing, and cellular reprogramming Specialized investigations into animal models, dairy production, gene-environment interactions, and wildlife health Development of emerging tools for precision plant and animal production systems Dr. Bordignon's work bridges fundamental biological mechanisms with practical agricultural innovations, emphasizing genomic and cellular approaches to enhance productivity while maintaining ecological balance and addressing global food system challenges.

Ramon Klein GeltinkView profile

Assistant Professor

• Immunometabolism
• T cell function
• Cancer Immunotherapy
• +7 more

Ramon Klein Geltink is an Assistant Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia's Faculty of Medicine, and an Investigator at BC Children's Hospital Research Institute (BCCHR). His research program focuses on understanding how immune cell metabolism influences function in both cancer and autoimmune conditions, with particular emphasis on childhood diseases. Dr. Klein Geltink's research interests center on immunometabolism, specifically how metabolic pathways regulate T cell function in cancer immunotherapy and autoimmune diseases. His lab investigates the role of metabolite availability, transport, enzyme expression, and cofactor availability in immune cell activation and function. Key research areas include adoptive cellular therapy, metabolic reprogramming of immune cells, and the application of metabolomic techniques to develop better treatments for children with immune-related diseases. Analysis of Dr. Klein Geltink's recent publications reveals a strong focus on CD8+ T cell metabolism in cancer immunotherapy, with particular attention to how nutrients like glutamine, fatty acids, and redox balance influence T cell function in the tumor microenvironment. His work bridges fundamental metabolic research with clinical applications, particularly in pediatric oncology and autoimmune disorders. The research spans from basic metabolic mechanisms to translational applications, with several publications examining how metabolic interventions could improve cellular therapies. Dr. Klein Geltink collaborates extensively with clinicians and clinician-scientists at BCCHR to translate metabolic findings into potential therapeutic approaches. His lab utilizes biochemical and metabolomic techniques to understand immune cell metabolism and its implications for disease treatment. His research group includes multiple postdoctoral fellows, graduate students, and research assistants working on various aspects of immunometabolism. Dr. Klein Geltink's work has been supported by competitive funding mechanisms including CIHR Project Grants, indicating recognition of the significance and quality of his research program.

• Cellular Senescence
• Cancer Therapeutics
• Induced Pluripotent Stem Cells (iPSCs)
• +4 more

Christian Beauséjour is a Full Professor in the Department of Pharmacology and Physiology at the University of Montreal and a senior researcher at the Azrieli Research Center of CHU Sainte-Justine. His roles include teaching and supervising graduate students in pharmacology and physiology. Dr. Beauséjour holds dual affiliations with the Faculty of Medicine’s Department of Pharmacology and Department of Microbiology, Immunology, and Infectiology. He completed his PhD in Pharmacology at the University of Montreal (2001) and postdoctoral training at Berkeley National Laboratory and Berlex Biosciences in California. His career includes industry experience at Sangamo Biosciences (2004–2005), where he contributed to genome-editing techniques. Since 2005, he has led research on cellular senescence and iPSC-based therapies at CHU Sainte-Justine. Research Focus: Immunogenic properties of senescent cells and their role in cancer progression Development of senolytic therapies using induced pluripotent stem cells (iPSCs) Humanized mouse models to study cancer-immune interactions Grants and Collaborations: His research is supported by institutions such as the Canadian Institutes of Health Research (CIHR), Terry Fox Research Institute, and Fondation Charles Bruneau. Key projects include senescence clearance to enhance immune function and improving cancer immunotherapy efficacy through senolytic drugs. Laboratory: His team includes postdoctoral fellows (Damien Maggiorani, Joshua Dulong), research associates (Basma Benabdallah), and students (Marie-Lyn Goyer, Paola Saavedra). The lab established the CHU Sainte-Justine’s Cell Reprogramming and Genome Editing Platform in 2015.

Arezu Jahani-AslView profile

Associate Professor

• Cancer Biology
• Neuro-oncology
• Neuroscience
• +3 more

Dr. Arezu Jahani-Asl is an Associate Professor in the Department of Cellular and Molecular Medicine at the University of Ottawa’s Faculty of Medicine. She is affiliated with the U Ottawa Brain and Mind Institute and previously held a position at McGill University. Her research focuses on developing therapeutic strategies for brain diseases, particularly glioblastoma and neurodevelopmental disorders. She has secured funding from CIHR, the Cancer Research Society, and NSERC. Education: Bachelor of Science (2000), University of Toronto (Distinction, Golden Key Honor Society) Master of Science (Cellular & Molecular Medicine), University of Ottawa PhD (Neuroscience), University of Ottawa (CIHR Doctorate Award) Research Interests: Targeting glioblastoma stem cells and therapeutic resistance mechanisms Molecular pathways in neurodevelopmental disorders like Börjeson-Forssman-Lehmann syndrome Role of cytokine signaling in cancer progression Publications Trends: Her work spans Nature Neuroscience , Nature Communications , and Cell Reports , focusing on glioblastoma pathogenesis, signaling pathways in cancer, and genetic models of intellectual disability. Recent studies highlight OSMR’s role in radiation resistance and carbohydrate-binding proteins’ impact on cancer stem cells. Awards & Roles: FRQS Investigator Awards Board of Reviewing Editors at eLife CIHR Fellowship Committee Member Advising & Labs: Supervised over 20 trainees, with notable success in academic/industry careers. Her lab investigates neural stem cell reprogramming and cancer biology, collaborating with institutions like Harvard Medical School and the Ottawa Hospital Research Institute.

Peter ZandstraView profile

Professor

• Stem Cell Bioengineering
• Hematopoietic System
• Cellular Therapeutics
• +7 more

Dr. Peter Zandstra is a Professor at the University of British Columbia, holding affiliations with the Michael Smith Laboratories (MSL), School of Biomedical Engineering, and Department of Medical Genetics. His research focuses on stem cell bioengineering, particularly in generating functional tissues from stem cells with applications in blood diseases and regenerative medicine. He leads four core research pillars: multi-scale simulation, synthetic cell control, niche engineering, and cellular therapeutics. His work bridges computational modeling, experimental biology, and translational medicine. Dr. Zandstra holds prestigious titles including Fellow of the Canadian Academy of Health Sciences (CAHS), Fellow of the Royal Society of Canada (FRSC), and Member of the Order of Canada (CM). His lab has secured significant funding from organizations like the Stem Cell Network and has spun out companies like Notch Therapeutics. Recent breakthroughs include computational models predicting cell fate dynamics and discoveries about 'elite clones' in stem cell reprogramming. Education: PhD in Biomedical Engineering (not explicitly stated in text) Research Themes: Hematopoietic systems, gene regulatory networks, cell competition, and personalized medicine Awards: Killam Prizes, CAHS Fellowship, Order of Canada Lab facilities include advanced cell culture systems, bioreactors, and imaging tools. Collaborations with industry and academic institutions drive preclinical trials and therapeutic development. Dr. Zandstra actively mentors trainees and promotes interdisciplinary research in regenerative medicine.

Mousumi MajumderView profile

Professor

• Genotoxicology
• Breast Cancer Biology
• MicroRNA Regulation
• +4 more

Dr. Mousumi Majumder is a Professor and Tier II Canada Research Chair in Genotoxicology at Brandon University's Department of Biology. Her research focuses on understanding the molecular mechanisms of breast cancer progression, particularly exploring microRNA regulation, tumor microenvironment interactions, and biomarker discovery for early detection. She leads a lab investigating COX-2/EP4 signaling pathways, cancer stem cell biology, and lymphangiogenesis. Key achievements include securing a Breast Cancer Society of Canada grant (2022) and a Senate Award for Excellence in Research. Her work has been featured in CBC News, CTV Winnipeg, and Nature Portfolio for breakthroughs like blood-based biomarker development and anti-angiogenic therapies targeting EP4 receptors. She has trained numerous students, including Brady Nault (Research Manitoba MSc scholar), and collaborates on translational research to combat metastasis and chemoresistance. Affiliations: Brandon University, Breast Cancer Society of Canada Key Projects: miRNA-based diagnostics, tumor microenvironment modulation

• Cancer Biology
• Cellular Metabolism
• Oncology
• +3 more

Laura Hulea is an Accredited Professor affiliated with the Maisonneuve-Rosemont Hospital Research Center at the University of Montreal. Her research focuses on cancer metabolism, cellular energetics, and the role of signaling pathways like mTOR in oncogenesis and therapy resistance. Her work intersects biochemistry, molecular biology, and translational medicine, with applications in drug development for cancers such as multiple myeloma and acute myeloid leukemia. She investigates metabolic vulnerabilities in cancer cells and explores repurposing antidiabetic drugs like canagliflozin for oncology. Her studies span topics including mitochondrial function, protein synthesis regulation, and epigenetic modifications influencing tumor growth. Notably, her team examines how metabolic perturbations induced by environmental stressors or pharmacological agents can be exploited for therapeutic benefit. Recent work highlights the interplay between oncogenic kinases, translational control, and metabolic plasticity. Laura Hulea’s research emphasizes cross-disciplinary approaches to dissect how cellular metabolism and signaling pathways drive cancer progression. She has contributed to understanding how mTOR signaling impacts aging, lifespan, and mitochondrial dynamics, with implications for both cancer and age-related diseases. Her publications reflect a focus on translational research, aiming to bridge basic science and clinical applications.